3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
3
Phase 2
2
Phase 3
1
Phase 1
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
1
Conditions
Neuroendocrine Tumors
32
Multiple Endocrine Neoplasia Type 1
9
Neoplasms
8
Pituitary Neoplasms
7
Carcinoid Tumor
7
Pituitary ACTH Hypersecretion
6
Gastro-enteropancreatic neuroendocrine tumor
6
Differentiated Thyroid Cancer
6
Adrenocortical Carcinoma
6
Thyroid Cancer, Papillary
5
Pituitary Diseases
5
Pheochromocytoma
5
Thyroid Neoplasms
4
Serotonin Syndrome
4
Neuroblastoma
4
Cushing Syndrome
4
Breast Neoplasms
4
Acromegaly
4
ACTH Syndrome, Ectopic
4
Sarcoma
3
Liposarcoma
3
Insulinoma
3
Fibrosarcoma
3
Endometrial Neoplasms
3
Carcinoma, Medullary
3
Adenoma, Islet Cell
3
Adenocarcinoma, Follicular
3
Sarcoma, Synovial
2
Sarcoma, Endometrial Stromal
2
Parkinson Disease
2
Interventions
lanreotide
1
Solutions
1
Radiosurgery
1
Injections
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Growth Hormone-Secreting Pituitary Adenoma
×
Endocrine
×
Clear all
NCT03439709
2018-03-01
MERGE
Samsung Medical Center
Phase 3
Unknown
90 enrolled